EUVIMEDEUVIMED entdecken
Crossref

Protective effects of COVID ‐19 vaccination in splenectomized patients with immune thrombocytopenia

Xiang Liu, Xinai Gan iD, Jing Xu iD, Yutong Wang, Jie Huang, Xu He, Yan Li, Yuping Gong iD, Bing Peng, Ting Niu iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Xiang Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Splenectomy, Purpura, Thrombocytopenic, Idiopathic, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University, Key Research and Development Program of Sichuan Province, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Splenectomy is an effective treatment for immune thrombocytopenia (ITP). The effect of COVID‐19 vaccination on splenectomized patients with ITP during the COVID‐19 pandemic has not been reported. Therefore, this study aimed to investigate the effect of COVID‐19 vaccination on clinical outcomes in these patients. This was a longitudinal study of splenectomized patients with ITP. A total of 191 splenectomized patients were included in this study. After a median follow‐up of 114 months, 146 (76.4%) patients had a sustained response to splenectomy. During COVID‐19 infection, vaccinated patients showed a lower risk of severe infections (odds ratio [OR], 0.13; 95% confidence interval [CI]: 0.05–0.36; p < 0.001), hospitalization (OR, 0.13; 95% CI, 0.04–0.48; p = 0.002), and ITP exacerbation (OR, 0.16; 95% CI, 0.04–0.67; p = 0.012). These findings indicate that COVID‐19 vaccination plays a protective role in splenectomized patients with ITP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SplenectomyPurpura, Thrombocytopenic, IdiopathicCOVID-19COVID-19 VaccinesSARS-CoV-2HumansMaleFemaleMiddle AgedAdultVaccinationAgedLongitudinal StudiesHospitalization

Stichwörter der Autor:innen

COVID‐19immune thrombocytopeniasplenectomyvaccination

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • West China School of Medicine, Sichuan University, Chengdu, China.
  • Department of Hematology, Nanchong Central Hospital, Nanchong, Sichuan, China.
  • Department of Hepatopancreatobiliary Surgery, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Xinai Gan, Jing Xu, Yuping Gong, Ting Niu

Förderung

  • 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
  • Key Research and Development Program of Sichuan Province
  • National Key Research and Development Program of China
  • Sichuan Natural Science Foundation
  • Natural Science Foundation of Sichuan Province

Zitieren

APA

Liu, X., Gan, X., Xu, J., Wang, Y., Huang, J., He, X., Li, Y., Gong, Y., Peng, B., & Niu, T. (2024). Protective effects of COVID ‐19 vaccination in splenectomized patients with immune thrombocytopenia. British Journal of Haematology. https://doi.org/10.1111/bjh.19405

Vancouver

Liu X, Gan X, Xu J, Wang Y, Huang J, He X, et al. Protective effects of COVID ‐19 vaccination in splenectomized patients with immune thrombocytopenia. British Journal of Haematology. 2024. doi:10.1111/bjh.19405

BibTeX
@article{Liu2024,
  author = {Liu, Xiang and Gan, Xinai and Xu, Jing and Wang, Yutong and Huang, Jie and He, Xu and Li, Yan and Gong, Yuping and Peng, Bing and Niu, Ting},
  title = {Protective effects of COVID ‐19 vaccination in splenectomized patients with immune thrombocytopenia},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19405}
}
Kostenlos starten →